HUP9801886A2 - Eljárás megfelelően kapcsolódó cisztinhidakat tartalmazó inzulin-prekurzorok előállítására - Google Patents

Eljárás megfelelően kapcsolódó cisztinhidakat tartalmazó inzulin-prekurzorok előállítására

Info

Publication number
HUP9801886A2
HUP9801886A2 HU9801886A HUP9801886A HUP9801886A2 HU P9801886 A2 HUP9801886 A2 HU P9801886A2 HU 9801886 A HU9801886 A HU 9801886A HU P9801886 A HUP9801886 A HU P9801886A HU P9801886 A2 HUP9801886 A2 HU P9801886A2
Authority
HU
Hungary
Prior art keywords
cysteine
precursor
hydrochloride
temperature
precurzors
Prior art date
Application number
HU9801886A
Other languages
English (en)
Inventor
Reinhold Keller
Franz-Josef Rubröder
Original Assignee
Hoechst Marion Roussel Deutschland Gmbh.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Marion Roussel Deutschland Gmbh. filed Critical Hoechst Marion Roussel Deutschland Gmbh.
Publication of HU9801886D0 publication Critical patent/HU9801886D0/hu
Publication of HUP9801886A2 publication Critical patent/HUP9801886A2/hu
Publication of HUP9801886A3 publication Critical patent/HUP9801886A3/hu
Publication of HU228161B1 publication Critical patent/HU228161B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A találmány tárgya javítőtt eljárás megfelelően kapcsőlódócisztinhidakat tartalmazó inzűlinők vagy inzűlinszármazékőkprekűrzőrának az előállítására cisztein vagy cisztein-hidrőklőrid éskaőtróp segédanyag jelenlétében. Az eljárás az alábbi lépésekből áll: (a) az inzűlinők vagy inzűlinszármazékők prekűrzőrának vizesszűszpenzióját őlyan mennyiségű ciszteinnel vagy cisztein-hidrőklőriddal elegyítik, amely a prekűrzőr egy ciszteinmaradékáravőnatkőztatva 1-15 cisztein vagy cisztein-hidrőklőrid SH-maradékőtjelent, (b) a prekűrzőrnak a ciszteint vagy cisztein-hidrőklőridőt tartalmazószűszpenzióját körülbelül 8-tól körülbelül 11,5-ig terjedő pH-értékmellett, körülbelül 15-től körülbelül 55 řC-ig terjedő hőmérsékleten akaőtróp segédanyag 4-9-mőláris őldatába viszik, az így kapőttkeveréket mintegy 10-60 percig ezen a hőnmérsékleten tartják, majd (c) az elegyet körülbelül 8-tól körülbelül 11,5-ig terjedő pHmegtartásával, körülbelül 5 řC-tól körülbelül 30 řC-ig terjedőhőmérsékleten őlyan mennyiségű vízbe viszik, amelynek hőzzáadása azelegyben a cisztein vagy cisztein-hidrőklőrid kőncentrációjátkörülbelül 1-5 milliőmőlárisra, és a kaőtróp segédanyagkőncentrációját 0,2-1,0 mőlárisra állítja. ŕ
HU9801886A 1997-08-18 1998-08-17 Improved process for producing inzulin precurzors and-derivatives having with availably bonded cystin-bride HU228161B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19735711A DE19735711C2 (de) 1997-08-18 1997-08-18 Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken

Publications (4)

Publication Number Publication Date
HU9801886D0 HU9801886D0 (en) 1998-10-28
HUP9801886A2 true HUP9801886A2 (hu) 1999-01-28
HUP9801886A3 HUP9801886A3 (en) 1999-06-28
HU228161B1 HU228161B1 (en) 2013-01-28

Family

ID=7839275

Family Applications (2)

Application Number Title Priority Date Filing Date
HU9801886A HU228161B1 (en) 1997-08-18 1998-08-17 Improved process for producing inzulin precurzors and-derivatives having with availably bonded cystin-bride
HU0600287A HU228203B1 (en) 1997-08-18 1998-08-17 Process for production of insulin or indulin-derivatne having correctly linked cystine bridges

Family Applications After (1)

Application Number Title Priority Date Filing Date
HU0600287A HU228203B1 (en) 1997-08-18 1998-08-17 Process for production of insulin or indulin-derivatne having correctly linked cystine bridges

Country Status (21)

Country Link
US (3) US5986048A (hu)
EP (2) EP0906918B1 (hu)
JP (1) JP4291900B2 (hu)
KR (2) KR100537842B1 (hu)
CN (3) CN1483831B (hu)
AR (1) AR016821A1 (hu)
AT (2) ATE217636T1 (hu)
AU (1) AU744824B2 (hu)
BR (2) BRPI9816233B8 (hu)
CA (1) CA2245151C (hu)
CZ (1) CZ295679B6 (hu)
DE (3) DE19735711C2 (hu)
DK (2) DK0980874T3 (hu)
ES (2) ES2176870T3 (hu)
HK (3) HK1018464A1 (hu)
HU (2) HU228161B1 (hu)
ID (1) ID20717A (hu)
PL (1) PL191901B1 (hu)
PT (2) PT906918E (hu)
RU (2) RU2205836C2 (hu)
TR (1) TR199801587A3 (hu)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19735711C2 (de) * 1997-08-18 2001-04-26 Aventis Pharma Gmbh Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken
DE19930676B4 (de) 1999-07-02 2006-01-19 Sanofi-Aventis Deutschland Gmbh Verfahren zur Stabilisierung von Insulin, Insulinderivaten und/oder deren Vorläufer in komplexen Mischungen bei deren Lagerung in wäßrigen Lösungsmitteln
WO2001046453A1 (en) * 1999-12-22 2001-06-28 Novo Nordisk A/S Method for extractive refolding of scrambled single-chain polypeptides
WO2002004481A2 (en) * 2000-07-12 2002-01-17 Eli Lilly And Company Process to increase protein stability
DE10235168A1 (de) * 2002-08-01 2004-02-12 Aventis Pharma Deutschland Gmbh Verfahren zur Reinigung von Preproinsulin
DE102004015965A1 (de) * 2004-04-01 2005-10-20 Aventis Pharma Gmbh Verfahren zur Gewinnung von Insulinen durch verbesserte Luftbegasung der Faltung
MY143274A (en) 2005-12-22 2011-04-15 Genentech Inc Recombinant production of heparin binding proteins
TWI476207B (zh) * 2006-07-14 2015-03-11 Genentech Inc 重組蛋白之再摺疊
KR20110016430A (ko) * 2007-07-03 2011-02-17 암젠 인코퍼레이티드 봉입체 건량을 이용한 단백질 측정
RU2451750C2 (ru) * 2007-09-24 2012-05-27 Общество С Ограниченной Ответственностью "Герофарм" Способ получения рекомбинантного с-пептида проинсулина человека
AU2009203809B2 (en) 2008-01-09 2013-07-25 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
EP2274318B1 (en) * 2008-04-30 2014-08-13 Wockhardt Limited Processes for refolding of insulin
EP3228320B1 (de) 2008-10-17 2019-12-18 Sanofi-Aventis Deutschland GmbH Kombination von einem insulin und einem glp-1-agonisten
AR080669A1 (es) 2009-11-13 2012-05-02 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina
UY33025A (es) 2009-11-13 2011-06-30 Sanofi Aventis Deustschland Gmbh Composicion farmaceutica que comprende un agonista de glp-1 metionina
MX339614B (es) 2010-08-30 2016-06-02 Sanofi - Aventis Deutschland GmbH Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2.
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US20180282405A1 (en) * 2012-08-05 2018-10-04 Absci, Llc Cytoplasmic expression system
EP2931301B2 (en) 2012-12-17 2021-09-15 Merck Sharp & Dohme Corp. Process for purifying insulin and analogues thereof
EP3616727B1 (en) * 2013-02-26 2021-03-31 Hanmi Pharm. Co., Ltd. Insulin analog conjugates and use thereof
CN103694339B (zh) * 2013-12-04 2017-10-13 珠海联邦制药股份有限公司 一种甘精胰岛素前体的复性方法
EP3116531B1 (en) 2014-03-14 2021-10-20 Merck Sharp & Dohme Corp. Purifying insulin using cation exchange and reverse phase chromatography in the presence of an organic modifier and elevated temperature
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
CN104911203A (zh) * 2015-06-30 2015-09-16 成都易胜科生物科技有限公司 一种重组人胰岛素的工业制备方法
EP3344651B1 (en) 2015-09-02 2022-03-02 Merck Sharp & Dohme Corp. A process for obtaining insulin with correctly formed disulfide bonds
US10689430B2 (en) 2016-05-25 2020-06-23 Merck Sharp & Dohme Corp. Insulin receptor partial agonists
WO2018018613A1 (zh) 2016-07-29 2018-02-01 广东东阳光药业有限公司 一种提高抗体纯度的细胞培养基和培养方法
CN113773391B (zh) * 2020-06-09 2023-10-20 宁波鲲鹏生物科技有限公司 一种门冬胰岛素的制备方法
CN113773400B (zh) * 2020-06-09 2023-08-18 宁波鲲鹏生物科技有限公司 一种门冬胰岛素衍生物及其应用
CN113773396A (zh) * 2020-06-10 2021-12-10 宁波鲲鹏生物科技有限公司 一种地特胰岛素衍生物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199391A (en) * 1981-01-02 1985-12-13 Genentech Inc Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin
DE3501641A1 (de) * 1985-01-19 1986-07-24 Hoechst Ag, 6230 Frankfurt Verfahren zur gewinnung von insulin-vorlaeufern aus reaktionsgemischen, die bei der faltung von insulin-vorlaeufern aus den entsprechenden s-sulfonaten anfallen
IL95495A (en) * 1989-08-29 1996-10-16 Hoechst Ag Fusion proteins their preparation and use
DK0600372T3 (da) * 1992-12-02 1997-08-11 Hoechst Ag Fremgangsmåde til fremstilling af proinsulin med korrekt forbundne cystinbroer.
DE4405179A1 (de) * 1994-02-18 1995-08-24 Hoechst Ag Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken
JP4624495B2 (ja) * 1994-12-29 2011-02-02 フェリング・インターナショナル・センター・エス．・エー． ヒト・インスリンの生成
DE19735711C2 (de) * 1997-08-18 2001-04-26 Aventis Pharma Gmbh Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken

Also Published As

Publication number Publication date
ATE217636T1 (de) 2002-06-15
CA2245151C (en) 2009-10-06
ES2177178T3 (es) 2002-12-01
HU0600287D0 (en) 2006-05-29
DE59804121D1 (de) 2002-06-20
HK1119449A1 (en) 2009-03-06
HU228161B1 (en) 2013-01-28
KR19990023651A (ko) 1999-03-25
US5986048A (en) 1999-11-16
DK0906918T3 (da) 2002-09-09
ES2176870T3 (es) 2002-12-01
BR9803755A (pt) 2000-03-28
EP0906918A3 (de) 1999-08-11
EP0980874B1 (de) 2002-05-02
PT906918E (pt) 2002-10-31
US6727346B2 (en) 2004-04-27
RU2205836C2 (ru) 2003-06-10
AU8076398A (en) 1999-02-25
TR199801587A2 (xx) 1999-03-22
TR199801587A3 (tr) 1999-03-22
CA2245151A1 (en) 1999-02-18
PT980874E (pt) 2002-10-31
CZ259898A3 (cs) 1999-03-17
ATE217012T1 (de) 2002-05-15
CN1483831B (zh) 2012-06-13
US6380355B1 (en) 2002-04-30
BRPI9816233B8 (pt) 2021-05-25
KR100537842B1 (ko) 2006-03-23
DE19735711C2 (de) 2001-04-26
CZ295679B6 (cs) 2005-09-14
DK0980874T3 (da) 2002-08-19
DE19735711A1 (de) 1999-02-25
KR20050067371A (ko) 2005-07-01
BRPI9816233B1 (pt) 2016-09-27
AR016821A1 (es) 2001-08-01
CN101186940A (zh) 2008-05-28
EP0906918A2 (de) 1999-04-07
PL328108A1 (en) 1999-03-01
KR100574580B1 (ko) 2006-04-28
HK1018464A1 (en) 1999-12-24
HU228203B1 (en) 2013-01-28
HK1061870A1 (en) 2004-10-08
CN1483831A (zh) 2004-03-24
JP4291900B2 (ja) 2009-07-08
EP0906918B1 (de) 2002-05-15
CN101186940B (zh) 2012-02-08
EP0980874A1 (de) 2000-02-23
PL191901B1 (pl) 2006-07-31
DE59803985D1 (de) 2002-06-06
ID20717A (id) 1999-02-18
RU2302882C2 (ru) 2007-07-20
AU744824B2 (en) 2002-03-07
CN1209437A (zh) 1999-03-03
HU9801886D0 (en) 1998-10-28
CN1132845C (zh) 2003-12-31
JPH11130798A (ja) 1999-05-18
US20020156234A1 (en) 2002-10-24
HUP9801886A3 (en) 1999-06-28

Similar Documents

Publication Publication Date Title
HUP9801886A2 (hu) Eljárás megfelelően kapcsolódó cisztinhidakat tartalmazó inzulin-prekurzorok előállítására
DK255184A (da) Fremgangsmaade til fremstilling af optisk aktive carbazolderivater, nye r- og s-carbazolderivater, samt laegemidler, der indeholder disse forbindelser
DE60038449D1 (de) Arzneimittelwirkstoffe mit zwei kovalent verknüpften wirkstoffgruppen (natriumkanalblocker/p2y2 rezeptor agonist) zur behandlung von schleimhäuten
NO20021335D0 (no) C-peptid for forbedret fremstilling av insulin og insulinanaloger
BR8803180A (pt) Processo de obtencao de um oxido cerico
DE3588095D1 (de) Polypeptid, dessen Verfahren zur Herstellung und dieses enthaltende pharmazeutische Zusammensetzung und deren Benutzung
KR910004599A (ko) 1,3-디하이드로-1-(피리디닐아미노)-2h-인돌-2-온, 이들의 제조방법 및 이들의 약제로서의 용도
GR900100406A (en) Preparation process for a pharmaceutical treatment composition
ES8705411A1 (es) Procedimiento para preparar derivados de 1-piperazinacarboxamida
SE7605819L (sv) Nya propargyl-2-fenylaminoimidazolin-(2), dess syraadditionssalter, lekemedel innehallande dessa och forfarande for framstellning derav
ES2028838T3 (es) Procedimiento para la obtencion de nuevos derivados de 4,5-hidro-oxazoles.
KR840004169A (ko) 프로인슐린 전구물질 유사체로부터 인슐린을 제조하는 방법
DE3678498D1 (de) Cytidine-diphosphocholine salze, besonders geeignet fuer oralen gebrauch.
ES2086528T3 (es) Nuevos compuestos biciclicos sustituidos con amino.
KR880000415A (ko) 신규한 테트라하이드로벤조티아졸 및 그의 제조방법과 용도
JPS5334716A (en) Preparation of amide amine amphoteric surface active agent
HUT43594A (en) Process for production of new derivatives of izoxasole and medical compounds containing thereof
KR970705576A (ko) 페닐 펩티드, 이를 제조하는 방법, 및 이 펩티드를 함유하는 약제학적 조성물(phenyl peptides, method for preparing same, and pharmaceutical compositions containing said peptides)
JPS6485920A (hu)
ATE147268T1 (de) Hypoglycemische peptide
DK632187D0 (da) Ny forbedret fremgangsmaade til fremstilling af penicillansyrederivater
DE3262231D1 (en) A novel vasodilator compound, process for the preparation thereof and pharmaceutical compositions thereform
CO4410182A1 (es) Proceso para mejorar la pureza enantiomerica de aldehidos
ES2000879A6 (es) Un procedimiento para preparar una sal de acido inorganico de cloruro de n-(1(s)-etoxicarbonil-3-fenilpropil)-l-alanilo
CH609331A5 (en) Process for the preparation of 3-aryloxy-3-phenyl-propylamines